Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dare Bioscience Inc DARE

Healthcare Biotechnology
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial... see more

Recent & Breaking News (NDAQ:DARE)

Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

GlobeNewswire March 24, 2021

Daré Bioscience to Host Full Year 2020 Financial Results and Company Update Conference Call and Webcast on March 30, 2021

GlobeNewswire March 23, 2021

Daré Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-Oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Symptoms and Genitourinary Syndrome Associated with Menopause

GlobeNewswire March 22, 2021

Daré Bioscience to Participate in Upcoming Virtual Conferences

GlobeNewswire March 10, 2021

Daré Bioscience to Participate at the 33rd Annual Roth Conference

GlobeNewswire March 8, 2021

Daré Bioscience to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 2, 2021

Daré Bioscience to Participate in Maxim Group's Late Stage Innovations in Women's Health Virtual Event

GlobeNewswire February 25, 2021

Daré Bioscience to Participate at the Women's Health Innovation Series: Contraception Innovation Summit to be held Virtually on February 23, 2021

GlobeNewswire February 16, 2021

Daré Bioscience to Present at the 2021 BIO CEO & Investor Digital Conference

GlobeNewswire February 9, 2021

Daré Bioscience to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

GlobeNewswire January 5, 2021

Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis

GlobeNewswire December 7, 2020

Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update

GlobeNewswire November 12, 2020

Daré Bioscience to Host Third Quarter 2020 Financial Results and Company Update Conference Call and Webcast on November 12, 2020

GlobeNewswire November 5, 2020

Daré Bioscience to Present at the 2020 BIO Investor Forum Digital

GlobeNewswire October 7, 2020

Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)

GlobeNewswire September 21, 2020

Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences

GlobeNewswire September 8, 2020

Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré's Novel Pipeline of Women's Health Programs

GlobeNewswire September 1, 2020

Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis

GlobeNewswire August 20, 2020

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT1 Phase 1 Human Clinical Study for the Prevention of Preterm Birth

GlobeNewswire August 19, 2020

Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update

GlobeNewswire August 12, 2020